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There are exciting findings in the field of depression and coronary heart disease. Whether diagnosed or simply self-reported,
depression continues to mark very high risk for a recurrent acute coronary syndrome or for death in patients with coronary heart
disease. Many intriguing mechanisms have been posited to be implicated in the association between depression and heart disease,
and randomized controlled trials of depression treatment are beginning to delineate the types of depressionmanagement strategies
that may benefit the many coronary heart disease patients with depression.
1. Introduction
Depression is quickly becoming the leading cause of years of
life lived with disability worldwide [1] and has a particularly
large impact on compromised health when comorbid with
a chronic medical disorder [2]. More than 17 million
American adults survived after an acute coronary syndrome
(ACS), with 1.2 million new surviving cases added per year
[3]. More than 2 out of every 5 of these patients have
significant patient-reported depressive symptoms [4], and
these symptoms will remain long after discharge [5]. Thus,
as many as 7 million of Americans living with coronary heart
disease (CHD) are also suffering with clinically significant
depression, and we add half of a million new cases to this
public health burden annually. As the comorbidity between
these two conditions is high, and both predict increased
occurrence of the other, a whole field has emerged to study
the complex inter-relations of depression and ACS. For
example, presence of a depressive disorder and/or minimally
elevated depressive symptoms appears to be a robust risk
and prognostic marker of CHD recurrence and all-cause
mortality [4, 6, 7]. In this paper, the definition, measure-
ment, epidemiology, mechanisms, screening, and treatment
recommendations for depression comorbid with coronary
heart disease will be presented, as will the controversies
and future research directions in this interesting intersection
between mental and physical disease.
2. Defining Depression
Many researchers and much of the lay public assume that
depression is a categorical disorder, and that those who
suffer with symptoms typically associated with depression
have a disease qualitatively different from everyday distress.
Consequently, they consider that this cluster of symptoms
should be viewed as one of a series of psychiatric illnesses,
as described within the Diagnostic and Statistical Manual
of Mental Disorders (DSM) [8]. However, there are oth-
ers promoting continuous or dimensional views of these
symptoms. Both conceptualizations are reviewed, starting
with disease categories because some of the debates within
psychiatric nosology may shed light on the depression—
CHD association.
2.1. Depression as a Psychiatric Disorder. Depressive disor-
ders are syndromal diagnoses based on subjective experience
of psychological and somatic symptoms that are reported to
a professional who evaluates these symptoms along continua
of intensity, duration, and impact on daily functioning.
Categories from the DSM-IV [8] include major depressive
disorder, dysthymia, adjustment disorder with depressed
mood, depression due to a general medical condition, and
depression not otherwise specified (n.o.s.).
Differential depression disorder diagnosis is decided
based on the duration of the illness, the number of symptoms
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present, and the presumed etiology of the illness—all
of which are distinctions that should be reported when
investigating the link between depression and CHD. Major
Depressive Disorder (MDD) is the most commonly studied
clinical diagnosis in relation to CHD. It is characterized by
clinically significant impairment in at least five areas such
as appetite or sleep that have persisted for at least two
weeks, plus the presence of depressed mood or the loss of
pleasure/interest for most of the day during those two weeks.
In contrast, dysthymia is reserved for a cluster of symptoms
that persisted over a longer period. The number of symptoms
needed to diagnose dysthymia is less than in MDD, but
persistent depressed mood has to be present throughout two
years. Both MDD and dysthymia can be further specified
according to the presence or absence of atypical symptoms
such as reactive mood, hyperphagia (i.e., excessive eating),
hypersomnia, leaden paralysis, or longstanding interpersonal
rejection sensitivity.
The diagnosis of mood disorder due to a general medical
condition describes a significant disturbance in mood that is
directly related to the presence of a medical condition known
to cause depression, as long as the mood symptoms do not
meet criteria for other DSM-IV categories of depression.
Thus, there must be evidence that the psychiatric symptoms
are actually caused by the medical condition rather than
being just a reaction to being ill. One of the most clearly
documented examples of this type of depressive disorder
is the depression that results from Parkinson’s disease [9].
Although there is a high prevalence of elevated depressive
symptoms after an acute coronary syndrome (ACS) event,
no one has yet proposed that the ACS may cause these
symptoms; however, depressive symptoms can result from
cerebrovascular disease [10]. Thus, one intriguing possibility
is that depression due to a medical condition (vascular
depression in in this case) may be precipitated by the same
CVD risk factors as those responsible for the ACS.
Next, adjustment disorder is characterized by the develop-
ment of clinically significant emotional or behavioral symp-
toms in response to an identifiable psychological stressor.
The symptoms must develop within three months after the
onset of the stressor and must resolve within six months of
the termination of the stressor [11]. Severe physical events,
such as an ACS, can be a precipitant of an adjustment
disorder with depressed mood, but extreme mood distur-
bance would still be classified as a major depressive disorder
in DSM-IV, and symptoms lasting longer than six months
would similarly be classified as meeting criteria for a mental
disease. Might it be adjustment disorder that predicts ACS
recurrence? Only well-trained diagnostic staff, alert to the
sometimes subtle distinction between adjustment and other
depressive disorders, could address this question, and no
such study has classified sufficient numbers of ACS patients
with adjustment disorder to test this intriguing hypothesis.
Depression n.o.s. allows the classification of less severe
syndromes of depression (with fewer symptoms) of a shorter
duration (less than 2 weeks) that do not meet criteria for
major depressive disorder or dysthymia. It encompasses
DSM-IV research categories such as minor depression
and brief recurrent depressive disorder, which have also
been labelled as “subthreshold” depression, a category that
encompasses syndromes of depression that fail to meet
criteria for major depressive disorder [12], but which show
some significant impairment in social or occupational func-
tioning [13]. “Subthreshold” depression has been proposed
by investigators conducting longitudinal studies of mood
disorders (e.g., [14, 15]) to reflect normal fluctuations in
the longitudinal course of mood disorders, and a similar
construct has been found to predict CHD recurrence [16,
17]. Thus, the longitudinal course of depressive symptoms,
as well as subthreshold depression levels, must be carefully
assessed to determine if one or both are critical to ACS
prognosis.
More recent approaches to categorical classification have
addressed the problem of comorbid anxiety and depressive
illnesses. For example, a study by Kessler et al. [18] found
that up to 58% of patients with a lifetime diagnosis of
major depressive disorder may suffer from anxiety disor-
der(s), suggesting that the psychiatric diseases’ underlying
pathophysiologies may not respect DSM-IV boundaries. The
broad implications of this highly prevalent comorbidity are
that etiologies [19], neuroendocrine mechanisms [20], and
sequelae may be common to both diseases, so ACS patients
should be assessed for both anxiety and depressive disorders,
as well as histories of both, to more fully understand the
association of depression to ACS recurrence.
2.2. Assessment of Depression as a Psychiatric Disorder. Com-
mon assessment tools for reliable diagnosis of depressive
disorders include the Structured Clinical Interview for DSM-
IV (SCID; [21]) and the Diagnostic Interview Schedule (DIS;
[22]). The SCID is a semistructured interview designed
for administration by a clinician or trained mental health
professional to provide a basis for accurate DSM-IV diag-
noses. It exists in several versions (e.g., SCID-I for DSM
Axis I diagnoses, SCID-II for DSM Axis II (personality
disorders) diagnoses), and every diagnostic category (e.g.,
mood disorders) has its own module that can be used
separately. A research version is available which can be
modified, and research assistants without a clinical degree
can reliably administer this version after extensive training.
Test-retest reliability of the SCID ranges widely according to
setting and study population (e.g., Williams et al. [23]). Its
validity has not been extensively studied mostly because of
the lack of a “gold standard” for psychiatric diagnoses. In
contrast, the SCID itself is widely used as the gold standard
against which the sensitivity and specificity of self-report
measures is evaluated.
TheDIS can also be administered by trained nonclinician
interviewers. Its answers are completely precoded which
enhances reliability; however, the DIS is rather inflexible
and some have argued that it is insensitive to change [24].
The DIS served as one basis for the development of the
Depression Interview and Structured Hamilton [24] (DISH:
a semistructured interview developed for the Enhancing
Recovery in Coronary Heart Disease (ENRICHD) study).
The DISH was designed to assess the severity of
depressive symptoms and enable trained interviewers to
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make a DSM-IV major depression, minor depression, and
dysthymia diagnosis in medically ill patients. Furthermore,
the lifetime and family history of these diagnoses is assessed.
The DISH was validated against the SCID (88% diagnostic
overlap) and in ENRICHD, clinicians agreed with 93% of
diagnoses made by research nurses [24]. It is likely the
best depression interview to be used with ACS patients, to
accurately determine if depression exists, rather than somatic
symptoms resulting from the cardiac disease.
2.3. Depression as Self-Reported Distress Symptoms. When
professionally trained interviewers are not available and/or
it is not feasible to conduct psychiatric diagnostic interviews,
reliance on self-report measures of depression for diagnostic
classification has been common in studies of CHD patients
[25]. There are many such measures, each with its own
merits, and some available in updated and/or shortened
versions. Each of these self-report measures was designed
to detect depressive disorders in various populations (such
as primary care patients, or older adults, or population-
based samples) and they detect depressive disorders and
demonstrate item consistency, split-half reliability, and sta-
bility to varying, but generally satisfactory degrees [25, 26].
Two of the most frequently used, the Beck Depression
Inventory (a trademarked inventory—both versions I and
II (see http://www.pearsonassessments.com/ for ordering
instructions)) [27, 28] and the Center for Epidemiological
Studies—Depression subscale (CES-D [29]), are also fre-
quently employed in studies of depressive symptoms and
CHD, and both have shown good predictive validity to ACS
events [30, 31]. However, of concern in choosing any of
these measures for use in a depression—CHD study is their
sensitivity and specificity for depression detection in older
patients with comorbid medical illnesses, who have recently
undergone a life-threatening medical crisis [32].
Unfortunately, discrepancies between what investigators
mean by the term “depression,” and how they then assess it,
may lead to erroneous conclusions, contradictory findings,
and difficulty in summarizing the evidence-base of the inter-
relationships between depression and CHD that has—or has
not—accrued.
3. Epidemiology and Prognostic
Significance of Depression Comorbid
with Coronary Heart Disease
3.1. Depression in CHD Patients Is Prevalent. An Agency for
Healthcare Research & Quality systematic review reported
that up to 20% of CHD patients meet criteria for a
major depressive disorder, and up to 47% have signifi-
cant patient-reported depressive symptoms, and these diag-
noses/symptoms remain long after discharge [5]. Thus, as
noted in a comprehensive review by Carney, almost 2 out
of every 5 ACS patients have clinically significant depression
[4]. This contrasts starkly with the general population, where
depression is seen in 4 to 7% persons [33]. When DSM
criteria are used to establish a diagnosis, prevalence tends
to be somewhat lower (i.e., 15 to 20%) in CHD patients,
but even minor depression or elevated depressive symptoms
are seen in 30 to 50% of these patients [34]. Importantly,
both clinically diagnosed depression and elevated depressive
symptoms predict increased cardiac risk, as described below.
3.2. Depression in CHD Patients Is Observationally Associated
with Diminished Health-Related Quality of Life. Depression
in both stable CHD patients and those with a recent ACS
clearly predicts impoverished health-related quality of life,
independent of traditional predictors of quality of life [35].
For example, recent ACS patients with a history of depression
have twice the rate of reported angina, triple the reported
physical limitations, and are at almost triple the risk of
diminished health-related quality of life [36]. Of multiple
predictors of one-year quality of life in a study of myocardial
infarction (MI) patients, including demographic and social
variables, severity of disease, and other predictors, depression
was the most important [37]. In another large study of CHD
patients, depression was once again the most important
correlate of diminished quality of life, while 2 traditional
measures of cardiac function, ejection fraction and ischemia,
were not [38]. In fact, a recent review demonstrated that
depression was more highly associated with health-related
quality of life & health status than angina, arthritis, asthma,
or diabetes [39]. There have been calls to improve quality of
life in post-ACS patients, rather than continue to focus on
extending life of diminished quality [40]. Treating depression
could answer this call.
3.3. Depression in CHD Patients Is Observationally Associated
with High Costs. Depression has long been associated with
high costs of medical utilization [42], many lost days of
productivity, and reduced performance while at work [43].
Patients who have a chronic medical condition such as
CHD, and comorbid depression, have significantly more
ambulatory visits, emergency room visits, days in bed
due to illness, and functional disability [44]. Five-year
cardiovascular health costs were 15–53% higher in women
with myocardial ischemia who were depressed compared to
those who were not depressed [45]. In post-MI patients with
elevated depressive symptoms, one year health care costs of
out-patient, emergency room, and readmission visit costs
(excluding mental health costs) were 41% higher than for
post-MI patients with few depressive symptoms [46].
3.4. Depression in CHD Patients Is Observationally Associated
with Poor Medical Prognosis. In addition to increased health
care utilization, death and morbidity are societal costs
associated with depression in post-ACS patients. Large
epidemiological studies have demonstrated convincingly that
depression is a predictor for occurrence and recurrence
of CHD. Depressive symptoms alone also predict CHD
risk, but stronger effect sizes have been observed for MDD
compared to depressive mood, suggesting a dose-response
relationship [31, 47, 48]. In addition to the enormous
patient and caregiver burden, post-MI patients who are
depressed have more medical comorbidities [49] and cardiac
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Figure 1: Hazard ratios of depressive symptoms and traditional cardiovascular risk factors.
compared to nondepressed post-MI patients [16, 49–51].
Prospective observational studies show, among ACS patients,
the hazard ratio associated with depressive symptoms is
1.80 (95% CI: 1.46–2.51) for all-cause mortality [52], and
1.95 (95% CI: 1.33–2.85) for MI recurrence [6]. A recent
meta-analysis indicates that elevated depressive symptoms
continue to strongly identify CHD patients at mortality risk
(relative risk: 3.41 (95% CI: 2.19–5.31)) [52]. As can be seen
in Figure 1, depressive symptoms in CHD patients is on par
with more conventional CHD recurrence prognostic factors
for predicting death and CHD recurrence.
The biology of depression suggests dysregulation of
several physiological systems, some of which are implicated
in the depression-CHD recurrence link [53]. However, the
evidence remains equivocal regarding which biological dys-
regulations are responsible for the link between depression
and CHD.
4. Mechanisms by Which Depression
May Confer Coronary Heart Disease
Recurrence and Death Risk
There are many behavioural and biological mechanisms
that have been proposed to explain the association between
depression and CHD [53, 54]. Biological mechanisms pro-
posed to explain the depression-CHD prognosis associa-
tion include platelet reactivity, inflammation, autonomic
imbalance, sleep architecture disruption, circadian rhythm
disruption anabolic/catabolic hormonal imbalance, as well
as many others [55–58]. A selected review of the evidence
available for many of the proposed mechanisms is provided
below.
4.1. Evidence for the Link between Platelet Reactivity and
Depression. Several case-control studies have demonstrated
the existence of platelet hyperreactivity in CHD patients
[59, 60]. In a study by Laghrissi-Thode et al. [60], higher
levels of platelet factor 4 and β-thromboglobulin, markers
of platelet aggregation, were described in MDD patients
with CHD compared with nondepressed CHD patients.
Serebruany et al. [61] pooled the data from 3 studies of
post-ACS patients: ASSENT-2, PRONTO, and SADHART,
the last of which specifically screened and enrolled MDD
patients. Fifty nonsmoking, nondiabetic subjects without
cardiovascular disease were also enrolled as controls. The
study showed that patients with CHD and MDD exhibited
the highest levels of platelet factor 4, β-thromboglobulin,
and platelet/endothelial cell adhesionmolecule-1 when com-
pared with MI or unstable angina patients without MDD.
4.2. Evidence for the Link between Inflammation and Depres-
sion. Several cross-sectional studies have linked depression
to chronic inflammation in otherwise healthy participants
[62–64], as well as in post-ACS patients shortly after
the index event [65, 66]. Elevated levels of inflammatory
biomarkers including c-reactive protein (CRP), soluble inter-
cellular adhesion molecule 1 (sICAM1), soluble vascular cell
adhesion molecule-1, and tumor necrosis factor-α (TNF-α)
are associated with an increased risk of cardiovascular events
in patients with known CHD including survivors of a recent
ACS [67–70].
CRP is significantly higher in depressed patients with
no CHD compared with matched nondepressed controls.
The cardiovascular health study enrolled patients aged 65+
years with no CHD history and found that participants
with increased depressive symptoms had higher CRP levels,
after adjusting for potential confounders [71]. Similarly,
recent findings from the ATTICA study demonstrated that
depressive symptoms were positively correlated with higher
CRP in 853 participants [72]. A recent analysis of the
National Health & Nutrition Examination (NHANES III)
survey found that patients with a history of MDD had
elevated CRP levels compared to patients with no history of
depression (OR = 1.64), independent of other standard CHD
risk factors [73]. Data also show that depressed patients have
elevated peripheral white blood cell counts and increased B-
and T-cell activity [74–77].
Similarly, sICAM1 has been cross-sectionally associated
with depression [78]. A recent study showed that the
expression of sICAM-1 on vascular endothelial cells in the
brain was associated with depression development [79].
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In addition, psychological stress (often associated with
depressive symptoms) increases sICAM-1 expression in
circulating granulocytes, lymphocytes, and monocytes [78].
Findings are similar for post-ACS patients. Four recent
studies have examined the relation between depression and
inflammatory biomarker levels after an ACS. Lespe´rance
et al. [80] showed that levels of sICAM-1 was related to
depression at a mean followup of 2 months after the ACS.
Additional analyses revealed that a significant relationship
was found between depression and elevated CRP levels only
in patients not taking statins. Miller et al. [81] showed
that depression was associated with increased CRP levels
independent of several possible confounders including statin
therapy in patients who had an acute coronary syndrome
event or coronary revascularization ≥3 months prior to
enrollment. There was no association between depression
and levels of interleukin-6 (IL-6) or TNF-α. Similarly, we
found that persistently elevated levels of depression 3months
following an acute coronary syndrome event were signifi-
cantly associated with elevated CRP levels, independent of
several possible confounders [82]. This was the case in both
patients who were prescribed statins at any time during the
three month period, and in those who were not. In contrast,
only one study has shown no significant association between
depression and elevated inflammatory biomarkers. Annique
et al. [83] showed that there was no relation between
several inflammatory markers such as CRP, TNF-α, IL-6, and
neopterine in depressed versus nondepressed patients post-
ACS at a mean followup of 6 months.
The immune system usually reacts to an inflamma-
tory stimulus with an induction of a T helper 2/anti-
inflammatory shift to protect the organism from excessive
T helper 1/proinflammatory cytokine release. However,
stress hormones such as cortisol are capable of facilitating
inflammation through further inducing the release of proin-
flammatory cytokines without the adaptive simultaneous
release of anti-inflammatory cytokines. In addition to an
elevation in proinflammatory markers, a reduction in anti-
inflammatory markers may also be associated with depres-
sion. Interleukin-10, an anti-inflammatory cytokine, was
examined in chronic heart failure patients with and without
depressive symptoms. Those with depressive symptoms
exhibited significantly lower levels of interleukin-10 and
higher levels of the proinflammatory cytokines TNF-α and
IL-6 [84]. These findings suggest that depression is associated
with a downregulation of anti-inflammatory cytokines with
a simultaneous upregulation of proinflammatory cytokines.
In summary, several studies indicate that depression
in CHD patients is associated with an increase in proin-
flammatory and a decrease in anti-inflammatory cytokines,
which are both associated with an increased risk of recurrent
cardiovascular events. Thus, a dysregulation in the inflam-
matory pathways may mediate the link between depression
and recurrent CHD.
4.3. Evidence for the Link between Autonomic Dysregulation
and Depression. Autonomic dysregulation is characterized
by increased activation of the sympathetic nervous system
(SNS), which usually acts in concert with a reduced acti-
vation of the parasympathetic nervous system (PNS). Both
elevated SNS activity and reduced PNS activity have been
implicated in depression and CHD recurrence.
Several studies have documented that depressed indi-
viduals compared to their nondepressed counterparts have
lower heart rate variability (HRV), a well-established non-
invasive index of cardiac autonomic regulation, although
these differences may be seen in different frequency bands.
Using data from the ENRICHD trial, Carney and colleagues
demonstrated that very low frequency (VLF) HRV was
lower in depressed post-MI patients compared to their
nondepressed counterparts and partially mediated the rela-
tionship between depression and mortality after MI [85].
While the underlying physiology of VLF HRV is not well
understood, the fact that it, along with low frequency
(LF) and high frequency (HF) power, is virtually elimi-
nated by the parasympathetic antagonist atropine suggests
a substantial vagal contribution [86]. In another analysis
from the ENRICHD dataset, HF, LF, VLF, and ultra-low
frequency (ULF) HRV were all lower in depressed versus
nondepressed post-MI patients [65]. After adjustment for
covariates, these differences remained statistically signifi-
cant for all but HF power. In healthy women from the
Women’s Health Initiative, several time domain indices of
HRV were lower among depressed participants compared
to those with no evidence of depression [87]. While there
are exceptions [88, 89], these data suggest that depres-
sion is associated with reduced cardiac parasympathetic
modulation.
Research on the relation between the activity of the
SNS and depression has a long history. Several studies
have shown increased catecholamine levels in depression,
although there have been exceptions [90, 91]. Esler et al. [92]
found increased norepinephrine (NE) spillover. The rate of
norepinephrine released to plasma from sympathetic nerves
in some but not all depressed patients. Wong and colleagues
measured cerebrospinal fluid (CSF) NE and plasma cortisol
each hour for 30 consecutive hours in controls and patients
with melancholic depression (MDD with specific additional
features including anhedonia or loss of interest and pleasure
in things or people) and demonstrated higher CSF NE and
plasma cortisol levels around the clock in the depressed
patients [93]. Veith and colleagues showed that depressed
patients had an increased rate of NE entry into the circulation
[94]. Other studies also have shown elevated levels of plasma
NE in depressed patients [95–97]. Recently, Gold et al.
demonstrated that severely depressed patients had increased
heart rate (HR), blood pressure (BP), CSF NE, and plasma
NE compared to a control group [98]. In a recent study
of 91 women, higher levels of depression were positively
associated with 24-hour urinary NE excretion [99]. The same
pattern of results emerged from the Heart and Soul Study
[100]. Among 598 patients with coronary heart disease, those
with depressive symptoms (n = 106) had greater mean 24-
hour urinary norepinephrine excretion levels and were more
likely to have norepinephrine excretion levels in the highest
quartile and above the normal range than those without
depressive symptoms. Thus, there is substantial evidence
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that both serum and urinary norepinephrine are typically
elevated in depressed patients.
4.4. Evidence for the Link between Autonomic Dysregulation
and CHD. There is abundant evidence that the autonomic
nervous system plays a significant role in the pathophysiol-
ogy of CHD recurrence. By enhancing myocardial electrical
stability, the parasympathetic nervous system reduces the
risk of sudden cardiac death. Animal experiments confirm
the capacity of higher levels of cardiac vagal regulation to
protect against sudden death after experimentally induced
MI [101], and HRV is a powerful predictor of sudden death
in heart failure patients [102] and in patients at elevated
risk for sudden death [103]. This effect may account for the
repeated finding that low levels of HRV confer elevated risk
of adverse events following an MI [104–106]. In post-CABG
patients randomized to the placebo condition in a trial of
gemfibrozil, low levels of HRV predicted the progression of
coronary atherosclerosis after controlling for conventional
risk factors [107].
Excess activity of the sympathetic nervous system pro-
duces many effects that contribute to CHD recurrence in
post-ACS patients. It raises blood pressure, increasesmyocar-
dial oxygen demand, activates platelets, induces myocyte
apoptosis, and is arrhythmogenic. Administration of β-
blockers, which protect against future events in post-MI
patients, is evidence of the role of SNS in adverse events.
Correspondingly, research suggests that diurnal changes
in indices of SNS activity, for example, catecholamines,
are associated with the diurnal pattern of the onset of
cardiovascular events, which more frequently happen in the
morning hours [108–112], with a meta-analysis concluding
that 1 in 11 myocardial infarctions are attributable to the
morning excess incidence [113]. Systemic a2-receptor block-
ade by yohimbine reduced the sympathetically-mediated
orthostatic increase in platelet aggregation significantly,
further suggesting the central role of the SNS in the risk of
thrombotic vascular events in atherosclerosis [114]. Patients
with evidence of coronary endothelial dysfunction show
increased vasoconstriction in response to catecholamines
[115].
4.5. Evidence for the Link between Sleep Architecture Dis-
ruption and Depression. Depression and sleep architecture
disruption are closely linked, although identification of the
specific polysomnographic parameters that are uniquely
dysregulated in depression remains controversial [116].
Total sleep time is decreased in depressed patients
and those prone to depressive episodes [117], and while
prospective data are lacking, disturbances that shorten sleep
duration (prolonged sleep latency, early morning awakening,
sleep continuity disturbances, and insomnia) have all been
suggested as possible contributors to depressed mood [118].
Cross-sectional studies of depressed versus nondepressed
patients regularly find that total sleep time is almost always
reduced in the depressed patients [116, 117, 119].
Reduced REM latency, the time from sleep onset to the
first occurrence of REM is the most frequently reported
sleep dysregulation that distinguishes MDD patients from
normals, other psychiatric patients, and those with nonen-
dogenous depression Benca 1992 [120]. A meta-analysis
drew the same conclusion [116].
Depressed patients tend to have decreased slow wave
sleep as reviewed by a meta-analysis incorporating results
from 177 studies with data from 7151 patients and controls
[116, 119, 121]. More recently, Armitage et al. reported that
compared to healthy subjects, slow wave sleep was decreased
in depressed outpatients [122]. Furthermore, antidepressant
use appears to reverse these sleep markers of depression, by
increasing total slow wave sleep and the slow wave sleep in
the first sleep cycle, but not in the second cycle [123].
4.6. Evidence for the Link between Sleep Architecture Disrup-
tion and CHD. While prospective epidemiological studies
relating many of the dimensions of sleep architecture to CVD
recurrence are lacking, there is epidemiological evidence
that short sleep duration is predictive of ACS incidence
[101, 124]. REM sleep is characterized by pronounced surges
of sympathetic activity [125] which may be of sufficient
magnitude (a) to stimulate thrombotic processes, (b) to
increase hemodynamic stress on vessel walls conducive to
plaque rupture, and (c) to alter cardiac electrophysiological
properties [126]. These autonomic surges could be responsi-
ble for cardiac events witnessed during REM sleep in humans
[127, 128]. Importantly, this REM-induced cardiac sympa-
thetic dominance is even more enhanced in individuals with
recent MI [129]. There is no evidence addressing the possible
role of slow wave sleep in predicting either ACS occurrence
or recurrence, but lack of restorative vagal regulation could
underly the association with ACS recurrence. Thus, we
only have indirect evidence that sleep architecture may be
implicated in CHD RECURRENCE/DEATH, but we do have
theoretical foundations for positing this association.
4.7. Evidence for the Link between Circadian Rhythm Disrup-
tion and Depression. Endogenous circadian rhythms regulate
daily variations in most of the hormonal, physiological, and
psychological variables implicated in depression as well as
ACS [130]. The systems with the most prominent variations
are thermoregulation or core temperature, and melatonin.
Core temperature, defined as the operating temperature
of an organism, specifically in deep structures of the body,
is seen as the gold standard for measurement of circadian
rhythm. Elevated nocturnal body temperature is one of
the more consistently observed circadian abnormalities in
depression [131–136]. Several studies show that during the
depressed phase, average temperature rises and temperature
amplitude (maximum temperature minus minimum tem-
perature) decreases. Effects of antidepressants on the core
body temperature of depressed patients include (a) lowering
of the minimum temperature during the night, and (b)
increasing temperature amplitude [133]. Electroconvulsive
therapy increases circadian amplitude and lowers core body
temperature in depressed subjects [136].
Melatonin is a pineal indoleamine derived from sero-
tonin and is a reliable marker of circadian rhythmicity in
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humans. Melatonin concentrations are increased at night
and are undetectable during the day. Depression-related
disturbances in the melatonin circadian profile in the form
of advanced phases and/or decrease in nocturnal amplitude
were demonstrated as early as 1979 [137–139] and have been
subsequently replicated [140–149].
4.8. Evidence for the Link between Circadian Rhythm Dis-
ruption and CHD. There is evidence that the majority
of cardiovascular events (including myocardial infarctions)
show a marked circadian rhythmicity with a peak incidence
between 6 am and 2 pm [113, 150]. However, in depressed
patients, for whom there are often circadian dysregulations,
themost prevalent time formyocardial infarctions is between
10 pm and 6 am [151]. Thus, circadian rhythm disruption in
depressed patients may help elucidate some of the pathways
by which these patients are at increased risk for recurrent
cardiovascular events.
4.9. Evidence for the Link between Anabolic/Catabolic Hor-
mone Imbalance and Depression. An adequate balance
between catabolic processes (energy mobilization), which
are induced by stress hormones such as catecholamines and
cortisol, and anabolic processes (repair, healing, growth),
which are induced by sex steroids, among others, is essential
for health and survival. Dehydroepiandrosterone (DHEA),
an anabolic sex steroid precursor, a marker frequently used
in combination with cortisol to capture anabolic/catabolic
hormone imbalance, has been implicated in protection
against coronary artery disease [152–154].
The hypothalamic-pituitary-adrenal (HPA) axis, the
major stress axis through which cortisol is released by
the adrenal gland when stimulated by adrenocorticotrophin
(ACTH), has been studied extensively in depression.
Depressed patients exhibit elevated circulating plasma lev-
els of ACTH and cortisol, and elevated urinary cortisol
concentration [155]. 24-hour sampling studies have found
increased cortisol secretion in depressed persons [155–158],
as well as alterations in the circadian rhythm of cortisol
[155–158]. Most studies on morning salivary cortisol have
demonstrated an increased awakening response in depressed
versus nondepressed subjects [159–161] but not all have
found this [162]. In 781 subjects from the CARDIA study
of heart disease in young adults, depression was associated
with flatter diurnal cortisol rhythm [163]. Pharmacological
challenge studies indicate diminished negative feedback in
the HPA axis in depressed persons [164].
There are several studies on the association of anabolic/
catabolic hormone balance with depression. The corti-
sol/DHEA ratio was greater in elderly patients with MDD
compared with age-matched healthy controls [165]. In
adolescents, high morning cortisol/DHEA ratios predicted
persistent MDD [73]. In a nonclinical sample of older men, a
high morning cortisol/DHEA ratio was associated with high
anxiety, negative mood, and deficits in various aspects of
cognitive function [166]. Young and colleagues showed that
a high cortisol/DHEA ratio in the evening was associated
with depression in an adult population [167]. In another
study, patients with major depressive disorder comorbid
with borderline personality disorder displayed elevated cor-
tisol/DHEA ratios relative to normal controls [168]. In sum,
there is evidence that anabolic/catabolic hormone imbalance
is observed in depression. Variation in study results is likely
to be due to the heterogeneity of depression as a phenotype
and the lack of standard measurement of this phenotype.
4.10. Evidence for the Link between Anabolic/Catabolic Hor-
mone Imbalance and CHD. Bain and colleagues prospec-
tively investigated serum cortisol during hospitalization
for acute MI and found that very high levels of cortisol
(>2000 nmol/L) predicted mortality [169], a finding that
was replicated by Karga and colleagues [170]. A high corti-
sol/DHEA ratio is thought to create an imbalance between
protein synthesis and degradation favoring catabolism over
anabolism in patients with chronic heart failure [171]. We
know of no studies demonstrating that an imbalance is
associated with CHD recurrence/death outcomes in post-
ACS patients. Cortisol and DHEA are both secreted in
response to ACTH released from the pituitary gland, hence,
the two steroids tend to correlate. In a study in intensive
care unit patients, age-adjusted correlations between early
morning DHEA and cortisol ranged between 0.47 (surgical
intensive care unit patients), 0.62 (medical intensive care unit
patients), and 0.69 (neurologic intensive care unit patients)
[172]. In contrast to cortisol, DHEA has been associated
with antidepressive and neuroprotective properties, and the
cortisol/DHEA ratio has been discussed as a measure of
the relative activity of the two steroids with two types of
hormone profiles posing an “endocrine risk”: higher cortisol
levels with normal DHEA, and normal cortisol levels with
lower DHEA leading to the same functional outcome [173].
4.11. Summary of Biological Mechanisms. While many prom-
ising mechanisms have been reviewed, we have little direct
human evidence that any of these are causally implicated in
the pathogenesis associated with depression comorbid with
CHD. A recent review of animal studies [174] suggests that
most of the above mechanisms continue to be plausible,
but until we move into human experiments or trials, there
remains many future studies that are required to definitively
answer which biological mechanisms are implicated in the
depression—ACS recurrence association.
4.12. Evidence for the Link between Behavioral Mechanisms
and Depression. Depression may also influence post-ACS
outcomes through its effects on a patient’s behaviors, such
as adherence to prescribed medications [175, 176] and/or
to secondary prevention recommendations after ACS [177].
In addition, there may be disparities in the way the health-
care system behaves towards depressed patients, and these
differences, for example, the treatment they receive, may
lead to worse outcomes [178]. Although it is now widely
accepted that depression after ACS predicts poorer medical
prognosis, there remains a gap in our knowledge about which
of the proposed behavioral mechanisms might explain this
association.
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Prior research shows that overall, a diagnosis of depres-
sion is associated with poor adherence among patients with
a number of chronic medical illnesses, including HIV [179],
hypertension [180], diabetes [181], and ACS [182]. Our own
research has shown that patients with persistent depressive
symptoms after ACS are also less likely to adhere to secondary
CHD prevention behaviors such as exercising regularly and
quitting smoking [177]. Furthermore, we have data showing
that as compared to nondepressed patients, patients with
depression are at greatest risk for poor medication adherence
[183].
In the case of ACS, not only secondary prevention behav-
iors, but behaviors pertaining to managing ACS symptoms
have been shown to impact medical outcomes. For example,
delay in the time from when patients develop symptoms
of chest pain to the time that they present for medical
care is clearly associated with worse post-ACS prognosis
[184]. A recent publication indicates that depressed patients
take on average 12 hours longer than nondepressed patients
to present to ER [185]. While intermediary depression
phenotypes were not differentiated in this sample, it may be
the Melancholic depressed patients who largely explain this
difference.
Finally, as a result of the cognitive, affective, and social
characteristics of mental illnesses, patients with depression
can be stigmatized by their illness [186]. This stigma may
lead to lower rates of treatment for cardiac disease, or
poorer communication about secondary prevention behav-
iors. Patients with depression tend to have flat affect and to
be less engaging; they therefore may be most susceptible to
such physician bias. Indeed, differences in the receipt of ACS
treatment among patients with and without mental illness
have been documented. Druss et al. showed that individuals
with co-morbid mental disorders were less likely to undergo
coronary revascularization procedures than those without
mental disorders [178].
4.13. Evidence for the Link between Poor Adherence Behaviors
and CHD. Poor adherence to behaviors recommended for
managing medical illnesses is well established as an impor-
tant factor in determining medical outcomes for a range of
diseases. For example, in a meta-analysis comparing high
adherers with low adherers across a broad group of illnesses,
treatment adherence accounted for 26% of the difference in
outcomes [187]. Nonadherence to cardiovascular medica-
tions after ACS is clearly linked with poor medical outcomes.
For example, Biondi-Zoccai et al. published a meta-analysis
of the hazards of not adhering to aspirin among 50,279
CAD patients and showed that aspirin nonadherence was
associated with a 3-fold higher MACE risk [188]. Gehi et
al. showed that self-reported nonadherence to medications
independently predicted adverse cardiac events (hazard ratio
2.3, 95% CI 1.3–4.3) in a cohort of stable CAD patients
followed for nearly four years [189]. Rasmussen et al. showed
an advantage in long-term survival in response to improved
cardiovascular drug adherence after MI in a population-
based sample [176]. Discontinuation of aspirin, statins,
and beta blockers was independently associated with higher
mortality (HR 3.81; 95% CI 1.88–7.72) in a cohort of
1,521 post-MI patients when medication use was assessed by
patient-report [175].
4.14. Evidence for the Link between Medication Adherence
and Depression. Although there are a number of potential
behavioral mechanisms linking depression and post-ACS
outcomes, poor medication adherence represents the most
promising and best-supported mechanism for explaining
this association. For example, in a study of 940 outpatients
with stable CHD, 14% of patients with major depression
reported that they were not taking their medication as
prescribed, compared to five percent of patients without
depression [190]. In contrast, in this same population
of patients with stable CHD, no association was found
between inflammation markers, a potential biological mech-
anism linking depression with post-ACS outcomes, and
the complex phenotype of depression [191]. While these
studies strengthen the causal link between nonadherence
to cardiovascular medications and outcomes in post-ACS
patients, they assessed medication adherence by self-report
or by administrative databases rather than by using electronic
medication monitoring, which is the gold-standard for
measuring adherence. Furthermore, these studies did not
consider patients from across the full spectrum of ACS
diagnoses.
Among post-ACS patients, we have reported that 42% of
persistently depressed patients took their prescribed aspirin
less than three-fourths of the time, while only 10.5% of non-
depressed patients demonstrated this level of nonadherence
(P < .001) [192]. In a separate analysis of this same group of
patients using a cross-lagged path analytic model, we showed
that improvements in depressive symptoms in the first
month after the ACS were associated with improved aspirin
adherence in the subsequent two months (standardized
direct effect −0.32, P = .016) [183], further establishing
the close relationship between depression and medication
adherence.
4.15. Behavioral Mechanism Summary. Clearly, more de-
tailed information on the mechanisms linking depression
to CHD outcomes is needed to better tailor interventions.
Confirming that electronically-monitored adherence is a
mediator of this relationship in depressed patients will pro-
vide the evidence needed to develop tailored interventions
for this subgroup of depressed post-ACS patients. Further-
more, assessing whether other patient and systems/physician
behavioral factors additionally mediate poor outcomes can
further inform the development of tailored interventions,
and our understanding of how depression confers post-ACS
prognostic risk.
5. Screening for Depression Comorbid
with Coronary Heart Disease
5.1. Depression in CHD Patients Should Be Screened for
and Treated, according to Numerous Guidelines. The strength
of the depression to CHD outcome observational findings
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reviewed above has led many to advise routine depression
screening for all CHD patients and referral for treatment
when indicated, the approach incorporated into the recent
advisory from the American Heart Association (AHA)
[41] and endorsed by the American Psychiatric Associa-
tion. Specifically, the advisory recommends administering
a depression screening questionnaire to ACS patients and
referring those who screen positive to a professional qualified
to diagnose and manage depression (see Figure 2). We now
have advisories/guidelines from AHA [41, 193], American
Academy of Family Practitioners [194], European profes-
sional cardiology societies [195], and the British health care
system [196] all endorsing depression screening in CHD
patients, and then referral for treatment if depression is
detected. However, there are no randomized controlled trials
(RCTs) to inform this large, potentially expensive health care
policy/guideline screening recommendation.
5.2. Perceived Barriers Interfere with Implementation of
Depression Screening and Comprehensive Treatment in CHD
Patients. In one recent examination of a quality initiative for
depression screening, provider reported barriers to depres-
sion screening for CHD patients included: too little time,
lack of professionals to refer to, and lack of education about
logistics and usefulness [197]. Similarly, a 2012 education
pretest offered by Medscape before a continuing medical
education exercise on management of depression in patients
with CHD revealed that the top three barriers reported by
both cardiologists and primary care providers were: too little
time, insufficient mental health network referrals, and lack
of evidence to support this approach (January 2012; personal
communication).
5.3. Health-Related Quality of Life Improvements and Cost
Effectiveness of Providing CHD Patients with the AHA
Depression Screen and Treat Algorithm Are Unknown. There
is a paucity of information from either observational or
randomized controlled trials to estimate the costs and
benefits of screening and treating depression in post-ACS
patients. Only one randomized sertraline placebo-controlled
trial, SADHART [198] (n = 369) has been used to estimate
costs, but this did not include cost-effectiveness and was not
a depression screening RCT [199]. This analysis noted that
many costs were not represented, as they were not collected.
A meta-analysis of RCTs testing depression screening
with only notification of depression severity to primary
care providers for primary care patients (NOT post-ACS
patients) found that this strategy did not lead to increased
detection or treatment of depression, and showed no impact
on health-related quality of life, depressive symptoms, or
other patient outcomes, including cost effectiveness [200].
An update of this Cochrane review found essentially the same
disappointing results [201]. In a recent study examining
the costs of conducting annual, lifetime, or every 5 year
depression screening for primary care patients, the costs
per QALY were unacceptable: the expected annual cost
was $192,444 /QALY [202]. A nonstationary Markov model,
using published literature, found that no depression screening
was preferable over annual depression screening, and in the
vast majority (99%) of scenarios, the cost per QALY was
more than $50,000, with little expectation of patient benefit
[202]. This heavy favoring of no screening makes sense
in a primary care setting in which depression’s association
with clinical outcomes is less robust than in a post-ACS
population. Thus, the evidence from RCTs in a primary
care population have found that providing primary care
patients with the depression screening and then treating
have minimal quality of life improvements, and/or are cost
ineffective.
5.4. The Importance of RCTs in Evidence-Based Clinical
Guidelines. Evidence-based practice guidelines are often
distinguished from consensus-based practice guidelines or
advisories, as the former systematically review all available
research on the specified topic, and then grade the level
of evidence to make a clinical recommendation [203, 204].
However, not all research designs are given equal weight;
standards of evidence for guidelines have evolved to place
greater emphasis on RCTs [205]. The reason for this is that
these designs are the most replicable, have the fewest sources
of bias, and all else being equal, have the greatest power to
detect evidence that a screening practice or treatment results
in a net benefit or net harm [206].
5.5. Screening Guidelines/Advisories in the Absence of RCT
Evidence Have Recently Been Extensively Criticized (and
Withdrawn). As of the writing of this paper, a controversy
is brewing over the reversal in one national screening
guideline’s recommendation [207–209]. Prostate cancer pre-
vention screening had been considered equivocally beneficial
by the U.S. Preventive Services Task Force (USPSTF) in 2002
[210] and 2008 [211], in large part because the observational
data and common sense of this approach (the USPSTF found
good evidence that PSA screening can detect early-stage
prostate cancer). However, USPSTF on review of the most
recent evidence, recently recommended against prostate-
specific antigen-based screening for prostate cancer (grade
D recommendation: there is moderate or high certainty that
screening has no net benefit) for all men in the general
US population, regardless of age [208]. They reversed their
screening recommendation by reviewing the current body of
evidence on the benefits and harms from recently conducted
RCTs, data that were not available when screening was first
thought to be useful. It is entirely possible that such a fate
could await screening for depression in CHD patients. That
is, current screening recommendations in clinical guidelines
and AHA advisories are consensus-, rather than evidence-
based, and the evidence, where it exists, does not favor
depression screening [212].
6. Randomized Controlled Trials
Treating Depression Comorbid with
Coronary Heart Disease
The establishment of depression as a risk marker in patients
with CHD prompted the National Heart, Lung, & Blood
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If symptoms persist 
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Determine appropriate treatment (antidepressants, cognitive 
behavioral therapy, or adjunctive interventions)
Carefully monitor for treatment adherence, drug 
efficacy and safety
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acute suicidality
follow-up within 1
Figure 2: American Heart Association’s Advisory for Depression Detection and Treatment (reprinted from Lichtman et al. [41]).
Institute to fund the Enhancing Recovery in CHD Patients
(ENRICHD) trial, which randomized almost 2500 patients
to determine whether treating depression and social isolation
after acute MI improves event-free survival. There were
no significant differences in all-cause mortality or nonfa-
tal MI between the intervention and usual care arms of
ENRICHD, nor in underpowered trials such as SADHART
[198] and MIND-IT [213]. ENRICHD and these first
generation phase II trials yielded only modest differences
in depression between the treatment and control arms.
Plausible reasons include: (1) the interventions were not
efficacious, (2) the treatments were not well accepted, (3) the
control conditions improved depressionmore than expected,
and (4) the appropriate patient population was not studied.
The ENRICHD investigators concluded that the next large,
Phase III trial should be postponed until more efficacious
depression treatments are available and the subtypes of
depression that are most responsible for increased medical
morbidity and mortality have been identified. Progress since
then includes the STAR∗D trial, [214] which demonstrated
that aggressive, stepped-care delivery of existing therapies
achieves better depression outcomes, several Phase II clinical
trials that have demonstrated better depression outcomes in
cardiac populations, and advances in our understanding of
the characteristics of high-risk depression subtypes.
Freedland et al. [215] conducted an RCT in 123 patients
withmajor or minor depression who had recently undergone
CABG surgery. The primary purpose of the trial was to
determine the efficacy of 2 behavioral treatments (cognitive
behavioral therapy [CBT] or supportive stress management)
compared with usual care. The depression effect size for CBT
at treatment end of 3 months was yielded a BDI depression
effect size of 0.85 (95% CI, 0.41–1.32). This effect was
maintained 6 months after the end of the trial.
Huffman and others recently completed a random-
ized controlled trials of 175 hospitalized depressed cardiac
patients [216]. They used a low-intensity depression collab-
orative care treatment, compared to usual care. The care
was initiated in hospital, and then continued by telephone.
Depression was assessed by the PHQ-9, using DSM-IVMDD
criteria. All patients in the treatment arm received behavioral
activation, and then by patient preference and/or prior treat-
ment history received psychotherapy or pharmacotherapy. At
3 months (treatment end), treated patients had PHQ-9 score
difference between group changes of −3.43 (95% CI:−5.41–
−1.45), and this was not quite maintained at 6months (when
no treatment was offered for the prior 3 months): −1.77
(95% CI: −3.76–0.22).
The COPES II [217, 218] post-ACS trial tested the
acceptability and efficacy of 6-month Stepped Depression
Care, a patient preference-driven, stepped algorithm depres-
sion intervention, to Referred Depression Care, in which
depression screening was followed by physician notification
of depression and encouragement to initiate depression
treatment. The protocol included 157 CHD patients with
depressive symptoms, and was not limited to those who met
DSM-IV criteria for major depressive disorder. This strategy
targeted the ACS patients who are at greatest mortality risk
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based on recent studies of depression and cardiac outcomes,
namely those with postdischarge depressive symptoms.
COPES II employed an aggressive, stepped care, patient
preference, symptom-driven approach that increased the
acceptability and efficacy of the depression intervention.
Depression treatment acceptability was three times higher in
the stepped depression care group than in the referred care
group. The differential change in depression between groups
yielded an effect size of 0.59 (95% CI, 0.18–1.00).
Whether the COPES intervention can be delivered as
intended in multiple clinical centers was then addressed by
CODIACS I, a feasibility/vanguard study conducted at 5 U.S.
sites [219]. In this vanguard, the COPES protocol has been
streamlined, case-findingmademore efficient, and treatment
delivery centralized and conducted by a web-based interface
and then by telephone. Leading experts have concluded that
it is time to conduct the next Phase III depression trial in
CHD patients [220–223], as to date, treating depression after
ACS has not resulted in improved cardiovascular outcomes
[213, 224], primarily because we do not have large RCTs that
actually test this question.
7. Summary
CHD patients are quite likely to have subsyndromal or
syndromal depression, which is associated with compro-
mised quality of life, increased health care and societal costs,
increased recurrence of CHD, and shortened life. We only
have one early, adequately powered trial to test if depression
reduction improved morbidity and mortality, and it did not
[224]. We have few randomized controlled trials on which
to base treatment decisions, but recent ones suggest that
patient preference, collaborative care, and cognitive behav-
ioral therapy all have promise for decreasing depression rates
and improving quality of life. Clinicians should only screen
for depression in their patients with CHD if they have the
resources and system to conduct a thorough psychiatric
diagnostic workup, refer or support patients found to be
at imminent harm, and provide the depression treatment
options needed to manage this relapsing, remitting disorder.
For health care providers who do not have such a depression
management system in place, referrals to appropriate sources
of depression care is a better way to proceed. However, it
behooves all of us to remain vigilant to the cardiovascular
risk factor management issues that are faced by a depressed
patient. Increasing structure, support systems, and other
facilitators of adherence are important in these patients,
as adherence is often a behavioral challenge they cannot
manage. Finally, in the absence of more definitive tests of the
biological and behavioral mechanisms by which depression
may confer CHD risk in CHD patients, and in the absence of
definitive trials testing if treating depression reduces this risk,
we remain unsure if depression is a potent treatment target,
or epiphenomena.
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